Levonorgestrel hormone releasing intrauterine system (Mirena®) as a contraceptive in egg donors: case report

被引:0
|
作者
C. Kailasam
V. Akande
U. D. Gordon
机构
[1] University of Bristol,Centre for Reproductive Medicine
[2] University of Bristol,Division of Obstetrics and Gynaecology, St Michael’s Hospital
[3] University of Bristol,Centre for Reproductive Medicine
关键词
Contraception; egg donor; IVF; Mirena coil;
D O I
暂无
中图分类号
学科分类号
摘要
We report the safe use of levonorgestrel hormone releasing intra uterine system (Mirena®) as a contraceptive in egg donors during a treatment cycle. In the first case report, a 29-year-old egg donor using the Mirena coil for contraception and two egg recipients, aged 41 years and 32 years respectively underwent standard IVF treatment, oocyte retrieval in the egg donor and in vitro fertilization followed by embryo transfer in the recipient. The outcome of IVF cycle using donor eggs was satisfactory with successful pregnancy in the egg recipient. The second case involved a 34-year-old egg donor using the Mirena coil and a 44-year-old recipient. Our findings suggest that egg donors can safely use the (Mirena®) as a contraceptive device during treatment, without compromising follicular development and oocyte quality.
引用
收藏
页码:137 / 140
页数:3
相关论文
共 50 条
  • [1] Levonorgestrel hormone releasing intrauterine system (Mirena®) as a contraceptive in egg donors:: case report
    Kailasam, C
    Akande, V
    Gordon, UD
    [J]. JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2005, 22 (03) : 137 - 140
  • [2] Mirena - Levonorgestrel-releasing intrauterine system
    不详
    [J]. FORMULARY, 2001, 36 (02) : 93 - 93
  • [3] Levonorgestrel-releasing intrauterine system (Mirena) for contraception
    McCarthy, Lisa
    [J]. AMERICAN FAMILY PHYSICIAN, 2006, 73 (10) : 1799 - 1801
  • [4] Acute urticaria as a side effect of the Mirena (levonorgestrel-releasing intrauterine system): A case report
    Chen X.
    Wu X.
    Zhu H.
    [J]. BMC Research Notes, 7 (1)
  • [5] COMBINED ADMINISTRATION OF DIENOGEST AND LEVONORGESTREL - RELEASING INTRAUTERINE SYSTEM MIRENA
    Tokhunts, K. A.
    Khudaverdyan, A. D.
    Abgaryan, N. B.
    Nahapetyan, N. A.
    Manvelyan, V. L.
    [J]. NEW ARMENIAN MEDICAL JOURNAL, 2022, 16 (03): : 86 - 90
  • [6] Evaluation of Quality of Life and Sexual Functioning of Women Using Levonorgestrel-Releasing Intrauterine Contraceptive System - Mirena
    Skrzypulec, Violetta
    Drosdzol, Agnieszka
    [J]. COLLEGIUM ANTROPOLOGICUM, 2008, 32 (04) : 1059 - 1068
  • [7] Endometrial adenocarcinoma in association with a levonorgestrel-releasing intrauterine system (Mirena®)
    Ndumbe, FM
    Husemeyer, RP
    [J]. JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE, 2006, 32 (02): : 113 - 114
  • [8] Mirena® -: the levonorgestrel intrauterine system -: The new contraceptive option for parous women -: Introduction
    Johansson, EDB
    [J]. MIRENA - THE LEVONORGESTREL INTRAUTERINE SYSTEM: THE NEW CONTRACEPTIVE OPTION FOR PAROUS WOMEN, 1998, : 9 - 10
  • [9] Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena®) in Campinas, Brazil
    Diaz, J
    Bahamondes, L
    Monteiro, I
    Petta, C
    Hildalgo, MM
    Arce, XE
    [J]. CONTRACEPTION, 2000, 62 (02) : 59 - 61
  • [10] Levonorgestrel-releasing intrauterine system (Mirena®) as a therapy for endometrial hyperplasia and carcinoma
    Bahamondes, L
    Ribeiro-Huguet, P
    de Andrade, KC
    Leon-Martins, O
    Petta, CA
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2003, 82 (06) : 580 - 582